Puma Venture Capital

Investment decisions are led by co-founder Amit Hazan, who has over 25 years of medical technology research and investing experience, including his most recent role as a Managing Director at Goldman Sachs. He is joined by Dr. Fred Moll, a pioneering surgical robotics entrepreneur and Intuitive Surgical co-founder, and Scott Zinober, former Senior Portfolio Manager for healthcare at Viking Global Investors. The firm also draws on the clinical judgment of co-founder Dr. Vipul Patel and the network of more than 20 surgeon venture partners.

Deal flow is generated primarily through the firm's network of over 20 surgeon key opinion leaders, who practice across the most relevant surgical specialties and are embedded as venture partners. These clinicians provide early access to technologies under development, insight into clinical adoption challenges, and relationships across the robotics and AI ecosystems where founders often emerge. The investment team overlays this clinical sourcing with its private- and public-market investing lens to filter opportunities.

Puma Venture Capital does not specify a single investment stage publicly, but its structure as an early-stage venture practice—with partners who are active entrepreneurs and clinicians—suggests a focus on early through growth-stage companies within the medical robotics and AI ecosystems. The firm's stated goal is to support founders reshaping medical procedures, which typically requires capital deployment from initial commercial validation through scale-up.

The firm concentrates on the robotics and AI ecosystems across all medical procedures. Its investment areas include robotic and autonomous systems, intelligence and embodied AI agents, intelligent infrastructure, procedural visualization and navigation, and next-generation surgical instrumentation. The strategy spans platforms that improve patient outcomes, boost labor productivity, and reduce system-wide healthcare costs.

Puma VC is built around a permanent network of more than 20 practicing surgeon venture partners—not part-time advisors—paired with a deal team whose backgrounds combine Wall Street medtech investing, hands-on robotics company building, and public-market portfolio management. This creates an institutionalized sourcing-and-diligence model where clinical insight is embedded directly into the investment process, giving the firm unusual access to early-stage technical and adoption signals.